Data as of Dec 19
| +12.64 / +6.06%|
Puma Biotechnology, Inc. is a development stage biopharmaceutical company. It acquires and develops innovative products for the treatment of various forms of cancer. The company focuses on in-licensing drug candidates that are undergoing or have already completed initial clinical testing for the treatment of cancer and then seek to further develop those drug candidates for commercial use. Puma Biotechnology was founded by Alan H. Auerbach on September 15, 2010. Its predecessor company, Innovative Acquisitions Corp was originally incorporated in Delaware in April 2007 as a shell company and later acquired and merged itself into Puma Biotechnology, Inc. in October 2011. The company is headquartered in Los Angeles, CA.
|Alan H. Auerbach||Chairman, President & Chief Executive Officer|
|Charles R. Eyler||Treasurer & Senior Vice President-Administration|
|Richard Paul Bryce||Senior VP-Clinical Research & Development|
|Mariann Ohanesian||Senior Director-Investor Relations|